Alerts will be sent to your verified email
Verify Email
BIOCON
|
Biocon
|
|
|---|---|
|
Operational Metrics
|
|
|
Pharmaceutical Sector
|
|
|
Domestic Sales Growth - YoY
|
7.7 % |
|
R&D as a % of Total Sales
|
8.0 % |
|
Financials
|
|
|
5 yr Average ROE
|
9.2 % |
|
5yr average Equity Multiplier
|
2.34 |
|
5yr Average Asset Turnover Ratio
|
0.39 |
|
5yr Avg Net Profit Margin
|
10.15 % |
|
Price to Book
|
2.13 |
|
P/E
|
41.21 |
|
5yr Avg Cash Conversion Cycle
|
-81.57 Days |
|
Inventory Days
|
82.47 Days |
|
Days Receivable
|
91.14 Days |
|
Days Payable
|
232.53 Days |
|
5yr Average Interest Coverage Ratio
|
15.21 |
|
5yr Avg ROCE
|
9.08 % |
|
5yr Avg Operating Profit Margin
|
27.02 % |
|
5 yr average Debt to Equity
|
0.58 |
|
5yr CAGR Net Profit
|
-12.56 % |
|
5yr Average Return on Assets
|
4.23 % |
|
Shareholdings
|
|
|
Promoter Holding
|
60.64 % |
|
Share Pledged by Promoters
|
0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.03 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
6.06 % |
|
Biocon
|
|
|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|